GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » Cash Flow for Lease Financing

Percheron Therapeutics (ASX:PER) Cash Flow for Lease Financing : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Percheron Therapeutics Cash Flow for Lease Financing?

Percheron Therapeutics's Cash Flow for Lease Financing for the six months ended in Dec. 2023 was A$0.00 Mil. Percheron Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Compared with last quarter (A$0.00 Mil in Jun. 2023 ), Percheron Therapeutics's Cash Flow for Lease Financing remained the same in Dec. 2023 (A$0.00 Mil).

Percheron Therapeutics Cash Flow for Lease Financing Historical Data

The historical data trend for Percheron Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Cash Flow for Lease Financing Chart

Percheron Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Percheron Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Percheron Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Percheron Therapeutics Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Percheron Therapeutics (ASX:PER) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » Cash Flow for Lease Financing
Comparable Companies
ASX:LV1 ASX:NXS ASX:MVP ASX:LGP ASX:VIT ASX:IVX ASX:EOF ASX:ECS ASX:CAN ASX:IDT ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ
Traded in Other Exchanges
ATHJF:USA AWY0:Germany
Address
14 Wallace Avenue, Toorak, VIC, AUS, 3142
Website
https://www.antisense.com.au
Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals. The company operates in two segments that have been identified based on its antisense oligonucleotide products as ATL1102 and ATL1103.

Percheron Therapeutics (ASX:PER) Headlines

No Headlines